Ciara M Kelly, Li-Xuan Qin, Karissa A Whiting, Allison L Richards, Viswatej Avutu, Jason E Chan, Ping Chi, Mark A Dickson, Mrinal M Gounder, Mary Louise Keohan, Sujana Movva, Benjamin A Nacev, Evan Rosenbaum, Travis Adamson, Samuel Singer, Edmund K Bartlett, Aimee M Crago, Sam S Yoon, Sinchun Hwang, Joseph P Erinjeri, Cristina R Antonescu, William D Tap, Sandra P D'Angelo
PURPOSE: Epacadostat, an indole 2,3 dioxygenase 1 (IDO1) inhibitor proposed to shift the tumor microenvironment toward an immune-stimulated state, showed early promise in melanoma but has not been studied in sarcoma. This study combined epacadostat with pembrolizumab, which has modest activity in select sarcoma subtypes. EXPERIMENTAL DESIGN: This phase 2 study enrolled patients with advanced sarcoma into five cohorts including i) undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma, ii) liposarcoma (LPS), iii) leiomyosarcoma (LMS), iv) vascular sarcoma, including angiosarcoma and epithelioid hemangioendothelioma (EHE), and v) other subtypes...
March 27, 2023: Clinical Cancer Research